SE9601397D0 - Use of growth hormone - Google Patents

Use of growth hormone

Info

Publication number
SE9601397D0
SE9601397D0 SE9601397A SE9601397A SE9601397D0 SE 9601397 D0 SE9601397 D0 SE 9601397D0 SE 9601397 A SE9601397 A SE 9601397A SE 9601397 A SE9601397 A SE 9601397A SE 9601397 D0 SE9601397 D0 SE 9601397D0
Authority
SE
Sweden
Prior art keywords
growth hormone
medicament
treatment
individuals
metabolic
Prior art date
Application number
SE9601397A
Other languages
English (en)
Swedish (sv)
Inventor
Gudmundur Johannsson
Per Maarin
Lars Loenn
Malin Ottosson
Kaj Stenloef
Per Bjoerntorp
Lars Sjoestroem
Bengt-Aake Bengtsson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9601397A priority Critical patent/SE9601397D0/xx
Publication of SE9601397D0 publication Critical patent/SE9601397D0/xx
Priority to EP97919856A priority patent/EP0935469B1/en
Priority to JP09537020A priority patent/JP2000510451A/ja
Priority to SI9730466T priority patent/SI0935469T1/xx
Priority to NZ332105A priority patent/NZ332105A/xx
Priority to AU24190/97A priority patent/AU2419097A/en
Priority to ES97919856T priority patent/ES2187771T3/es
Priority to PCT/SE1997/000601 priority patent/WO1997038709A1/en
Priority to PT97919856T priority patent/PT935469E/pt
Priority to CA002250907A priority patent/CA2250907A1/en
Priority to DK97919856T priority patent/DK0935469T3/da
Priority to DE69717301T priority patent/DE69717301T2/de
Priority to AT97919856T priority patent/ATE228007T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Steroid Compounds (AREA)
SE9601397A 1996-04-12 1996-04-12 Use of growth hormone SE9601397D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE9601397A SE9601397D0 (sv) 1996-04-12 1996-04-12 Use of growth hormone
AT97919856T ATE228007T1 (de) 1996-04-12 1997-04-10 Verwendung von wachstumshormone
NZ332105A NZ332105A (en) 1996-04-12 1997-04-10 Medicaments including human growth hormone for the treatment of type II diabetes and metabolic syndrome
JP09537020A JP2000510451A (ja) 1996-04-12 1997-04-10 成長ホルモンの使用
SI9730466T SI0935469T1 (en) 1996-04-12 1997-04-10 Use of growth hormone
EP97919856A EP0935469B1 (en) 1996-04-12 1997-04-10 Use of growth hormone
AU24190/97A AU2419097A (en) 1996-04-12 1997-04-10 Use of growth hormone
ES97919856T ES2187771T3 (es) 1996-04-12 1997-04-10 Uso de la hormona del crecimiento.
PCT/SE1997/000601 WO1997038709A1 (en) 1996-04-12 1997-04-10 Use of growth hormone
PT97919856T PT935469E (pt) 1996-04-12 1997-04-10 Utilizacao da hormona de crescimento
CA002250907A CA2250907A1 (en) 1996-04-12 1997-04-10 Use of growth hormone
DK97919856T DK0935469T3 (da) 1996-04-12 1997-04-10 Anvendelse af væksthormon
DE69717301T DE69717301T2 (de) 1996-04-12 1997-04-10 Verwendung von wachstumshormone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9601397A SE9601397D0 (sv) 1996-04-12 1996-04-12 Use of growth hormone

Publications (1)

Publication Number Publication Date
SE9601397D0 true SE9601397D0 (sv) 1996-04-12

Family

ID=20402176

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9601397A SE9601397D0 (sv) 1996-04-12 1996-04-12 Use of growth hormone

Country Status (11)

Country Link
EP (1) EP0935469B1 (da)
JP (1) JP2000510451A (da)
AT (1) ATE228007T1 (da)
CA (1) CA2250907A1 (da)
DE (1) DE69717301T2 (da)
DK (1) DK0935469T3 (da)
ES (1) ES2187771T3 (da)
NZ (1) NZ332105A (da)
PT (1) PT935469E (da)
SE (1) SE9601397D0 (da)
WO (1) WO1997038709A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087090A (en) * 1997-02-25 2000-07-11 Celtrix Pharmaceuticals, Inc. Methods for predicting drug response
CA2294824A1 (en) * 1997-07-04 1999-01-14 Pharmacia & Upjohn Ab Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase b (pkb) activity
AU761880B2 (en) * 1998-11-26 2003-06-12 Auckland Uniservices Limited Treatment of hypertension
TW514510B (en) * 1999-06-11 2002-12-21 Tanita Seisakusho Kk Method and apparatus for measuring distribution of body fat
ATE381343T1 (de) * 1999-11-03 2008-01-15 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
SE0000837D0 (sv) 2000-03-13 2000-03-13 Pharmacia & Upjohn Ab New use
AU2006200127B2 (en) * 2000-03-13 2007-10-25 Pfizer Inc. Use of growth hormone in low dose
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
WO2003004068A1 (en) * 2001-07-06 2003-01-16 Auckland Uniservices Limited Hypertension treatment
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005020898A2 (en) 2003-08-21 2005-03-10 Tercica, Inc. Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i)
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268277A (en) * 1987-08-07 1993-12-07 Eniricerche S.P.A. Method for the preparation of human growth hormone

Also Published As

Publication number Publication date
NZ332105A (en) 2000-03-27
ATE228007T1 (de) 2002-12-15
DE69717301D1 (de) 2003-01-02
EP0935469A1 (en) 1999-08-18
EP0935469B1 (en) 2002-11-20
DE69717301T2 (de) 2003-09-04
PT935469E (pt) 2003-03-31
DK0935469T3 (da) 2003-03-17
WO1997038709A1 (en) 1997-10-23
JP2000510451A (ja) 2000-08-15
CA2250907A1 (en) 1997-10-23
ES2187771T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
SE9601397D0 (sv) Use of growth hormone
Poirier et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients
Blair et al. Sustained compression and healing of chronic venous ulcers.
DE69809558D1 (de) Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
UA83854C2 (uk) Застосування телмісартану для підвищення чутливості до інсуліну
EP0766966A3 (en) Method of treating insulin resistance
SE9201573D0 (sv) Use of igf-1
JP2009519949A5 (da)
ATE290863T1 (de) Verwendung von prolactinmodulatoren und diät zur herstellung eines medikamentes zur behandlung der fettleibigkeit
WO2002070546A3 (en) Modified derivatives of cck-8
Ampudia-Blasco et al. A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications?
FR2836336B1 (fr) Utilisation dans un traitement cosmetique d'une fraction phenolique riche en dihydrochalcones
EP1393738A4 (en) MEDICINE AGAINST DIABETES
Ashida et al. Effects of short-term hypocaloric diet on sympatho-vagal interaction assessed by spectral analysis of heart rate and blood pressure variability during stress tests in obese hypertensive patients
RU96115219A (ru) Способ лечения больных сахарным диабетом
ES2166406T3 (es) Uso de derivados de 1,5-benzodiazepina para el control del vaciado gastrico en pacientes con diabetes mellitus no dependiente de insulina.
ES2181923T3 (es) 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina.
CAMPBELL et al. Delayed brachial plexus palsy due to ununited fracture of the clavicle: Report of a case
Gupta et al. Volar compartment syndrome of the arm complicating a fracture of the humeral shaft: A case report
EA200600757A1 (ru) Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
Griebenow et al. D32 Hemodynamic effects of calcium antagonist/ACE-inhibitor combination therapy in essential hypertension
Griera et al. D33 Effect of doxazosin on insulin-resistance in non-obese mild-to-moderate hypertensive patients
Lima Jr et al. D35 Placebo effects in hypertensive urgency
US4788057A (en) Process for the treatment of psoriasis using typhoid vaccine